Neo-Synalar
RxNorm 1191359· NEOMYCIN SULFATE AND FLUOCINOLONE ACETONIDE· TOPICAL
Corticosteroid [EPC] · Eurofarma, Inc.
Indications and usage
INDICATIONS AND USAGE NEO-SYNALAR ® cream is indicated for the treatment of corticosteroid-responsive dermatoses with secondary infection. It has not been demonstrated that this steroid-antibiotic combination provides greater benefit than the steroid component alone after 7 days of treatment (see WARNINGS section) .
Dosage and administration
DOSAGE AND ADMINISTRATION NEO-SYNALAR ® cream is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Since NEO-SYNALAR ® cream is a water-washable vanishing cream, it is easily applied and leaves no traces.
Warnings
WARNINGS If local infection should continue or become severe, or in the presence of systemic infection, appropriate systemic antibacterial therapy, based on susceptibility testing, should be considered. Because of the concern of nephrotoxicity and ototoxicity associated with neomycin, this combination product should not be used over a wide area or for extended periods of time. There are articles in the current medical literature that indicate an increase in the prevalence of persons sensitive to neomycin.
Contraindications
CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. This product should not be used in the external auditory canal if the eardrum is perforated.
Pregnancy
Pregnancy Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Nursing mothers
Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- drug ineffective8
- application site erythema2
- application site irritation1
- application site swelling1
- breast cancer1
- condition aggravated1
- delusion1
- dermatitis atopic1
- erythema1
- nausea1
- off label use1
- seasonal allergy1
Adverse reactions (label)
ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria The following adverse reactions have been reported with the topical use of neomycin: Ototoxicity Nephrotoxicity
KR · 한국Products in Korea (21)
- 아시텔라케어연고(주)녹십자
- 아시텔라케어연고(주)녹십자
- 네오파신연고(황산네오마이신)(수출명:코랄라이트안티바이오틱연고)(주)씨엠지제약
- 네오파신연고(황산네오마이신)(수출명:코랄라이트안티바이오틱연고)(주)씨엠지제약
- 마데티카케어연고(주)퍼슨
- 마데티카케어연고(주)퍼슨
- 소푸라투루(황산네오마이신B)(주)한독
- 캄비손소프트크림(주)한독
- 캄비손소프트크림(주)한독
- 마데카솔케어연고동국제약(주)
- 마데카솔케어연고동국제약(주)
- 마데카솔케어연고동국제약(주)
- 캄비톤-에스크림삼진제약(주)
- 캄비톤-에스크림삼진제약(주)
- 더마스톤지크림에이치엘비제약(주)
- 더마스톤지크림에이치엘비제약(주)
- 네오미신연고(황산네오마이신)(수출명:Pure-aidAntibioticOintment)오스틴제약(주)
- 캄비스톤지크림청계제약(주)
- 캄비스톤지크림청계제약(주)
- 캄비스톤지크림청계제약(주)
View more: Full FDA label on DailyMed →Label effective 20260318